Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXE-346 in Ileal Pouch-Anal Anastomosis (PROF)
NCT05938465Phase 2Recruiting
- Sponsor
- ExeGi Pharma
- Start
- Nov 2023
- Primary completion
- May 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EXE-346 in Ileal pouch-anal anastomosis (IPAA) (4 arms), sponsored by ExeGi Pharma. Primary endpoints: Incidence, Severity, Relatedness, and Frequency of Treatment Emergent Adverse Events and Serious Adverse Events at 8 weeks, Number of Participants with Abnormal Physical Examinations at 8 weeks and 4 more. Started Nov 2023; status: recruiting.
02
Drugs
EXE-346
03
Conditions
Ileal pouch-anal anastomosis (IPAA)
Beyond the preview
Go deeper on NCT05938465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938465.